title: A preliminary quantitative proteomic analysis of glioblastoma pseudoprogression.
abstract: BACKGROUND
  Pseudoprogression disease (PsPD) is commonly observed during glioblastoma (GBM) follow-up after adjuvant therapy. Because it is difficult to differentiate PsPD from true early progression of GBM, we have used a quantitative proteomics strategy to identify molecular signatures and develop predictive markers of PsPD.
  
  
  RESULTS
  An initial screening of three PsPD and three GBM patients was performed, and from which 530 proteins with significant fold changes were identified. By conducting biological functional analysis of these proteins, we found evidence that the protein synthesis network and the cellular growth and proliferation network were most significantly affected. Moreover, six of the proteins (HNRNPK, ELAVL1, CDH2, FBLN1, CALU and FGB) involved in the two networks were validated (n = 18) in the same six samples and in twelve additional samples using immunohistochemistry methods and the western blot analysis. The receiver operating characteristic (ROC) curve analysis in distinguishing PsPD patients from GBM patients yielded an area under curve (AUC) value of 0.90 (95% confidence interval (CI), 0.662-0.9880) for CDH2 and.0.92 (95% CI, 0.696-0.995) for CDH2 combined with ELAVL1.
  
  
  CONCLUSIONS
  The results of the present study both revealed the biological signatures of PsPD from a proteomics perspective and indicated that CDH2 alone or combined with ELAVL1 could be potential biomarkers with high accuracy in the diagnosis of PsPD.
authors: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 TiantanXili, Dongcheng District, Beijing, 100050 China.
authors: Peng
authors: P
authors: Zhang
authors: Core Facility of Instrument, Institute of Basic Medical Sciences, Chinese Academy of Medical Science/School of Basic Medicine, Peking Union Medical College, No. 5 Dongdan Santiao, Dongcheng District, Beijing, 100005 China.
authors: Zhengguang
authors: Z
authors: Guo
authors: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 TiantanXili, Dongcheng District, Beijing, 100050 China.
authors: Yang
authors: Y
authors: Zhang
authors: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 TiantanXili, Dongcheng District, Beijing, 100050 China.
authors: Zhixian
authors: Z
authors: Gao
authors: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 TiantanXili, Dongcheng District, Beijing, 100050 China.
authors: Nan
authors: N
authors: Ji
authors: Core Facility of Instrument, Institute of Basic Medical Sciences, Chinese Academy of Medical Science/School of Basic Medicine, Peking Union Medical College, No. 5 Dongdan Santiao, Dongcheng District, Beijing, 100005 China.
authors: Danqi
authors: D
authors: Wang
authors: Core Facility of Instrument, Institute of Basic Medical Sciences, Chinese Academy of Medical Science/School of Basic Medicine, Peking Union Medical College, No. 5 Dongdan Santiao, Dongcheng District, Beijing, 100005 China.
authors: Lili
authors: L
authors: Zou
authors: Core Facility of Instrument, Institute of Basic Medical Sciences, Chinese Academy of Medical Science/School of Basic Medicine, Peking Union Medical College, No. 5 Dongdan Santiao, Dongcheng District, Beijing, 100005 China.
authors: Wei
authors: W
authors: Sun
authors: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 TiantanXili, Dongcheng District, Beijing, 100050 China.
authors: Liwei
authors: L
authors: Zhang
keywords: Pseudoprogression; Quantitative proteomics; iTRAQ labeling